REGENXBIO Inc. Shareholders' Equity
REGENXBIO Inc. (RGNX) had Shareholders' Equity of $71.77 million as of 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Balance Sheet › Equity › Equity, Attributable to Parent
us-gaap:StockholdersEquity · last filed 2026-08-06
- 2026-06-30: Stockholders' Equity Attributable to Parent $71.77M.
- 2026-03-31: Stockholders' Equity Attributable to Parent $21.08M.
- 2025-12-31: Stockholders' Equity Attributable to Parent $102.73M.
- 2025-09-30: Stockholders' Equity Attributable to Parent $161.45M.
| Period end | Stockholders' Equity Attributable to Parent |
|---|---|
| 2026-06-30 | $71.77M 10-Q · filed 2026-08-06 |
| 2026-03-31 | $21.08M 10-Q · filed 2026-08-06 |
| 2025-12-31 | $102.73M 10-Q · filed 2026-08-06 |
| 2025-09-30 | $161.45M 10-Q · filed 2025-11-06 |
| 2025-06-30 | $213.68M 10-Q · filed 2026-08-06 |
| 2025-03-31 | $274.20M 10-Q · filed 2026-08-06 |
| 2024-12-31 | $259.65M 10-Q · filed 2026-08-06 |
| 2024-09-30 | $301.42M 10-Q · filed 2025-11-06 |
| 2024-06-30 | $348.27M 10-Q · filed 2025-11-06 |
| 2024-03-31 | $390.67M 10-Q · filed 2025-08-07 |
| 2023-12-31 | $311.74M 10-K · filed 2026-03-05 |
| 2023-09-30 | $363.10M 10-Q · filed 2024-11-06 |
| 2023-06-30 | $405.86M 10-Q · filed 2024-11-06 |
| 2023-03-31 | $465.14M 10-Q · filed 2024-08-01 |
| 2022-12-31 | $516.20M 10-K · filed 2025-03-13 |
| 2022-09-30 | $563.82M 10-Q · filed 2023-11-08 |
| 2022-06-30 | $630.52M 10-Q · filed 2023-11-08 |
| 2022-03-31 | $689.67M 10-Q · filed 2023-08-02 |
| 2021-12-31 | $764.30M 10-K · filed 2025-03-13 |
| 2021-09-30 | $461.41M 10-Q · filed 2022-11-03 |
| 2021-06-30 | $507.25M 10-Q · filed 2022-11-03 |
| 2021-03-31 | $554.50M 10-Q · filed 2022-08-03 |
| 2020-12-31 | $377.75M 10-K · filed 2024-02-27 |
| 2020-09-30 | $415.66M 10-Q · filed 2021-11-02 |
| 2020-06-30 | $397.86M 10-Q · filed 2021-11-02 |
| 2020-03-31 | $420.15M 10-Q · filed 2021-08-09 |
| 2019-12-31 | $450.20M 10-K · filed 2023-02-28 |
| 2019-09-30 | $468.39M 10-Q · filed 2020-11-04 |
| 2019-06-30 | $494.59M 10-Q · filed 2020-11-04 |
| 2019-03-31 | $487.05M 10-Q · filed 2020-08-06 |
| 2018-12-31 | $508.85M 10-K · filed 2022-03-01 |
| 2018-09-30 | $494.06M 10-Q · filed 2019-11-05 |
| 2018-06-30 | $317.22M 10-Q · filed 2019-11-05 |
| 2018-03-31 | $299.34M 10-Q · filed 2019-08-07 |
| 2017-12-31 | $183.03M 10-K · filed 2021-03-01 |
| 2017-09-30 | $194.65M 10-Q · filed 2017-11-08 |
| 2017-06-30 | $211.70M 10-Q · filed 2017-08-08 |
| 2017-03-31 | $212.90M 10-Q · filed 2017-05-09 |
| 2016-12-31 | $161.74M 10-K · filed 2020-02-26 |
| 2016-09-30 | $180.23M 10-Q · filed 2016-11-09 |
| 2016-06-30 | $196.18M 10-Q · filed 2016-08-09 |
| 2016-03-31 | $208.60M 10-Q · filed 2016-05-05 |
| 2015-12-31 | $216.81M 10-K · filed 2019-02-27 |
| 2015-09-30 | $221.81M 10-Q · filed 2015-11-05 |
| 2014-12-31 | -$18.29M 10-K · filed 2018-03-06 |
| 2013-12-31 | -$13.92M 10-K · filed 2017-03-07 |
| 2012-12-31 | -$8.11M 10-K · filed 2016-03-03 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Entera Bio Ltd. (ENTX) | $0.485B | ||
| Tectonic Therapeutic, Inc. (TECX) | United States | $0.469B | -7.68 |
| Autolus Therapeutics plc (AUTL) | $0.506B | -1.52 | |
| Eikon Therapeutics, Inc. (EIKN) | United States | $0.446B | |
| Kyverna Therapeutics, Inc. (KYTX) | United States | $0.434B | -3.60 |
| Editas Medicine, Inc. (EDIT) | United States | $0.424B | -4.29 |
| Scribe Therapeutics, Inc. (SCTX) | United States | $0.410B | |
| Prime Medicine, Inc. (PRME) | United States | $0.557B | -3.54 |
| Zura Bio Ltd (ZURA) | $0.398B | -6.56 | |
| Surrozen, Inc./DE (SRZN) | United States | $0.395B |